
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Clinical decision support for small fiber neuropathy diagnosis, etiologic workup, and management">
      
      
      
        <link rel="canonical" href="https://blondarb.github.io/neuro-plans/drafts/small-fiber-neuropathy/">
      
      
      
      
        
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.7.1">
    
    
      
        <title>Small Fiber Neuropathy - Neuro Clinical Plans</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.484c7ddc.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.ab4e12ef.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../assets/css/custom.css">
    
    <script>__md_scope=new URL("../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#small-fiber-neuropathy" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="Neuro Clinical Plans" class="md-header__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Neuro Clinical Plans
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Small Fiber Neuropathy
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a4 4 0 0 0-4 4 4 4 0 0 0 4 4 4 4 0 0 0 4-4 4 4 0 0 0-4-4m0 10a6 6 0 0 1-6-6 6 6 0 0 1 6-6 6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 18c-.89 0-1.74-.2-2.5-.55C11.56 16.5 13 14.42 13 12s-1.44-4.5-3.5-5.45C10.26 6.2 11.11 6 12 6a6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
      <div class="md-header__source">
        <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="Neuro Clinical Plans" class="md-nav__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    Neuro Clinical Plans
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Home
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../clinical/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Interactive Clinical Tool
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3" >
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    Clinical Plans
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Clinical Plans
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Overview
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_2" >
        
          
          <label class="md-nav__link" for="__nav_3_2" id="__nav_3_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Seizures & Epilepsy
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_2">
            <span class="md-nav__icon md-icon"></span>
            
  
    Seizures & Epilepsy
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/status-epilepticus/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Status Epilepticus
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/new-onset-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    New Onset Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/breakthrough-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_3" >
        
          
          <label class="md-nav__link" for="__nav_3_3" id="__nav_3_3_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Stroke & Vascular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Stroke & Vascular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/acute-ischemic-stroke/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Ischemic Stroke
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/transient-ischemic-attack/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Transient Ischemic Attack
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/intracerebral-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Intracerebral Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/subarachnoid-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Subarachnoid Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_4" >
        
          
          <label class="md-nav__link" for="__nav_3_4" id="__nav_3_4_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuromuscular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/guillain-barre-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Guillain-Barré Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/myasthenia-gravis-crisis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenic Crisis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/myasthenia-gravis-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/neuromuscular-respiratory-failure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular Respiratory Failure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/peripheral-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Peripheral Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_5" >
        
          
          <label class="md-nav__link" for="__nav_3_5" id="__nav_3_5_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    CNS Infections
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_5_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_5">
            <span class="md-nav__icon md-icon"></span>
            
  
    CNS Infections
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/bacterial-meningitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bacterial Meningitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/hsv-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    HSV Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/autoimmune-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_6" >
        
          
          <label class="md-nav__link" for="__nav_3_6" id="__nav_3_6_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Spinal Emergencies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_6_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_6">
            <span class="md-nav__icon md-icon"></span>
            
  
    Spinal Emergencies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/acute-myelopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Myelopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/spinal-cord-compression-malignant/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Spinal Cord Compression (Malignant)
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/cauda-equina-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cauda Equina Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/epidural-abscess/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Epidural Abscess
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_7" >
        
          
          <label class="md-nav__link" for="__nav_3_7" id="__nav_3_7_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuro-Oncology
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_7_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_7">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuro-Oncology
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/brain-metastases/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_8" >
        
          
          <label class="md-nav__link" for="__nav_3_8" id="__nav_3_8_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Critical Care
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_8_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_8">
            <span class="md-nav__icon md-icon"></span>
            
  
    Critical Care
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/elevated-icp-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Elevated ICP Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_9" >
        
          
          <label class="md-nav__link" for="__nav_3_9" id="__nav_3_9_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Demyelinating
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_9_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_9">
            <span class="md-nav__icon md-icon"></span>
            
  
    Demyelinating
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/ms-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_10" >
        
          
          <label class="md-nav__link" for="__nav_3_10" id="__nav_3_10_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Headache
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_10_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_10">
            <span class="md-nav__icon md-icon"></span>
            
  
    Headache
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/migraine/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Migraine
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_11" >
        
          
          <label class="md-nav__link" for="__nav_3_11" id="__nav_3_11_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Movement Disorders
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_11_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_11">
            <span class="md-nav__icon md-icon"></span>
            
  
    Movement Disorders
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/parkinsons-disease-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Parkinson's Disease - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/essential-tremor/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Essential Tremor
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_12" >
        
          
          <label class="md-nav__link" for="__nav_3_12" id="__nav_3_12_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Dementia & Cognitive
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_12_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_12">
            <span class="md-nav__icon md-icon"></span>
            
  
    Dementia & Cognitive
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/dementia-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Dementia Evaluation
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/rapidly-progressive-dementia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Rapidly Progressive Dementia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_13" >
        
          
          <label class="md-nav__link" for="__nav_3_13" id="__nav_3_13_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Cranial Neuropathies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_13_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_13">
            <span class="md-nav__icon md-icon"></span>
            
  
    Cranial Neuropathies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/bells-palsy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bell's Palsy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_14" >
        
          
          <label class="md-nav__link" for="__nav_3_14" id="__nav_3_14_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Other
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_14_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_14">
            <span class="md-nav__icon md-icon"></span>
            
  
    Other
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/vertigo-dizziness-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Vertigo / Dizziness
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_4" >
        
          
          <label class="md-nav__link" for="__nav_4" id="__nav_4_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    References
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    References
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/lp-reference/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    LP Reference
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/tracker/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Template Tracker
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#section-a-action-items" class="md-nav__link">
    <span class="md-ellipsis">
      
        SECTION A: ACTION ITEMS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-b-reference" class="md-nav__link">
    <span class="md-ellipsis">
      
        SECTION B: REFERENCE
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#change-log" class="md-nav__link">
    <span class="md-ellipsis">
      
        CHANGE LOG
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-a-sfn-diagnostic-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX A: SFN Diagnostic Criteria
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-b-skin-biopsy-interpretation" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX B: Skin Biopsy Interpretation
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-c-autonomic-testing-interpretation" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX C: Autonomic Testing Interpretation
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              
              <article class="md-content__inner md-typeset">
                
                  

  <nav class="md-tags" >
    
      
      
      
      
        <a href="../../tags/#tag:autonomic" class="md-tag">autonomic</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:neuropathy" class="md-tag">neuropathy</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:outpatient" class="md-tag">outpatient</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:pain" class="md-tag">pain</a>
      
    
  </nav>


  
  


<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

<h1 id="small-fiber-neuropathy">Small Fiber Neuropathy<a class="headerlink" href="#small-fiber-neuropathy" title="Permanent link">&para;</a></h1>
<p><strong>DIAGNOSIS:</strong> Small Fiber Neuropathy (SFN)
<strong>ICD-10:</strong> G62.9 (Polyneuropathy, unspecified); G62.89 (Other specified polyneuropathies); G90.09 (Other idiopathic peripheral autonomic neuropathy)
<strong>SCOPE:</strong> Diagnosis and management of small fiber neuropathy presenting with painful sensory and/or autonomic symptoms with normal or near-normal nerve conduction studies. Includes length-dependent and non-length-dependent (ganglionopathy) patterns. Covers etiologic workup for treatable causes, symptomatic pain management, and autonomic symptom treatment.</p>
<p><strong>STATUS:</strong> Draft - Pending Review</p>
<p><strong>CLINICAL SYNONYMS:</strong> SFN; Small fiber sensory neuropathy; Small fiber predominant neuropathy; Pure small fiber neuropathy; Painful small fiber neuropathy; Autonomic small fiber neuropathy; Sensory ganglionopathy (non-length-dependent pattern)</p>
<hr />
<p><strong>PRIORITY KEY:</strong> STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>
<p><strong>KEY CLINICAL FEATURES:</strong>
- <strong>Definition:</strong> Neuropathy affecting small myelinated (Aδ) and unmyelinated (C) nerve fibers
- <strong>Sensory symptoms:</strong> Burning pain, allodynia, hyperalgesia, paresthesias, "pins and needles"
- <strong>Autonomic symptoms:</strong> Sudomotor dysfunction (dry skin, hyperhidrosis), orthostatic intolerance, GI dysmotility, urinary symptoms, sicca symptoms
- <strong>Key diagnostic criterion:</strong> Clinical neuropathy with normal or near-normal NCS (which test large fibers only)
- <strong>Gold standard confirmation:</strong> Skin biopsy with reduced intraepidermal nerve fiber density (IENFD)</p>
<hr />
<h2 id="section-a-action-items">SECTION A: ACTION ITEMS<a class="headerlink" href="#section-a-action-items" title="Permanent link">&para;</a></h2>
<hr />
<h2 id="1-laboratory-workup">1. LABORATORY WORKUP<a class="headerlink" href="#1-laboratory-workup" title="Permanent link">&para;</a></h2>
<h3 id="1a-essentialcore-labs">1A. Essential/Core Labs<a class="headerlink" href="#1a-essentialcore-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c</td>
<td>Diabetes and prediabetes are most common causes of SFN</td>
<td>&lt;5.7% normal; ≥5.7% prediabetes</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>Current glycemic status; impaired fasting glucose</td>
<td>&lt;100 mg/dL</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>2-hour oral glucose tolerance test (OGTT)</td>
<td>Impaired glucose tolerance causes SFN even with normal HbA1c</td>
<td>2-hr glucose &lt;140 mg/dL normal</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>BMP (creatinine, eGFR, electrolytes)</td>
<td>Renal function; medication dosing; uremic neuropathy</td>
<td>eGFR &gt;60; normal electrolytes</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>CBC</td>
<td>Baseline; anemia evaluation</td>
<td>Normal</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>B12 deficiency causes SFN; common and treatable</td>
<td>&gt;300 pg/mL (&gt;400 optimal)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>TSH</td>
<td>Hypothyroidism causes neuropathy</td>
<td>0.4-4.0 mIU/L</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>ESR, CRP</td>
<td>Inflammatory markers; vasculitis screen</td>
<td>Normal</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>ANA</td>
<td>Autoimmune etiology; Sjogren's screen</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Anti-SSA (Ro) and anti-SSB (La) antibodies</td>
<td>Sjogren syndrome is common cause of SFN (up to 40% of SFN)</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Hepatitis B and C serologies</td>
<td>HCV-associated neuropathy; cryoglobulinemia</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="1b-extended-workup-second-line">1B. Extended Workup (Second-line)<a class="headerlink" href="#1b-extended-workup-second-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylmalonic acid (MMA)</td>
<td>More sensitive for B12 deficiency if B12 borderline (200-400)</td>
<td>Normal (&lt;0.4 μmol/L)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Tissue transglutaminase IgA (TTG-IgA)</td>
<td>Celiac disease causes SFN even without GI symptoms</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Total serum IgA</td>
<td>IgA deficiency causes false-negative TTG</td>
<td>Normal (not deficient)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>SPEP/UPEP with immunofixation</td>
<td>Paraproteinemia; monoclonal gammopathy</td>
<td>No monoclonal protein</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>HIV</td>
<td>HIV-associated sensory neuropathy</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Lipid panel</td>
<td>Metabolic syndrome associated with SFN</td>
<td>Normal/controlled</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Deficiency associated with neuropathic pain</td>
<td>&gt;30 ng/mL</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Vitamin B1 (thiamine)</td>
<td>Deficiency causes painful neuropathy</td>
<td>Normal</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Vitamin B6</td>
<td>Both deficiency and excess cause neuropathy</td>
<td>Normal (neither high nor low)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Copper</td>
<td>Copper deficiency neuropathy (especially post-bariatric surgery)</td>
<td>Normal (70-140 μg/dL)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Zinc</td>
<td>Excessive zinc causes copper deficiency</td>
<td>Normal (not elevated)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Salivary gland biopsy</td>
<td>Sjogren syndrome if clinical suspicion high and serology negative</td>
<td>Negative for lymphocytic infiltration</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="1c-rarespecialized-refractory-or-atypical">1C. Rare/Specialized (Refractory or Atypical)<a class="headerlink" href="#1c-rarespecialized-refractory-or-atypical" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-galactosidase A enzyme activity</td>
<td>Fabry disease screening (X-linked; consider in males and females)</td>
<td>Normal enzyme activity</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>GLA gene sequencing</td>
<td>Confirm Fabry disease if enzyme low or high clinical suspicion</td>
<td>No pathogenic variants</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>TTR gene sequencing</td>
<td>Hereditary transthyretin amyloidosis; early SFN with autonomic symptoms</td>
<td>No pathogenic variants</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Fat pad or skin biopsy (Congo red)</td>
<td>Amyloidosis if suspected (autonomic features, cardiomyopathy, CTS)</td>
<td>No amyloid deposits</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Serum free light chains</td>
<td>AL amyloidosis screen</td>
<td>Normal kappa:lambda ratio</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Anti-FGFR3 antibodies</td>
<td>Autoimmune SFN (especially ganglionopathy pattern)</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Anti-TS-HDS antibodies</td>
<td>Autoimmune SFN marker</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Sarcoidosis workup (ACE, chest imaging)</td>
<td>Sarcoid neuropathy</td>
<td>Normal ACE; no hilar adenopathy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Paraneoplastic antibody panel</td>
<td>Paraneoplastic sensory ganglionopathy (anti-Hu) if rapid onset</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Cryoglobulins</td>
<td>Cryoglobulinemic neuropathy (especially with HCV)</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Schirmer test</td>
<td>Objective dry eye for Sjogren diagnosis</td>
<td>Normal (&gt;5mm in 5 min)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>SCN9A, SCN10A, SCN11A gene testing</td>
<td>Sodium channelopathies causing inherited SFN (erythromelalgia)</td>
<td>No pathogenic variants</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="2-diagnostic-imaging-studies">2. DIAGNOSTIC IMAGING &amp; STUDIES<a class="headerlink" href="#2-diagnostic-imaging-studies" title="Permanent link">&para;</a></h2>
<h3 id="2a-essentialfirst-line">2A. Essential/First-line<a class="headerlink" href="#2a-essentialfirst-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nerve conduction studies (NCS)</td>
<td>At initial evaluation</td>
<td>Normal or near-normal (SFN spares large fibers)</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Skin biopsy (3mm punch at distal leg and thigh)</td>
<td>After NCS shows normal large fiber function</td>
<td>Reduced IENFD below normative threshold for age/sex/site</td>
<td>Bleeding diathesis; anticoagulation (relative)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="2b-extended">2B. Extended<a class="headerlink" href="#2b-extended" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantitative sudomotor axon reflex test (QSART)</td>
<td>Autonomic symptoms; suspected sudomotor dysfunction</td>
<td>Normal sweat volumes at all sites</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Sudoscan</td>
<td>Screening for sudomotor dysfunction; non-invasive</td>
<td>Normal electrochemical skin conductance hands and feet</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Autonomic reflex screen (ARS)</td>
<td>Comprehensive autonomic evaluation; orthostatic symptoms</td>
<td>Normal cardiovagal, adrenergic, and sudomotor function</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Tilt table test</td>
<td>Orthostatic intolerance; POTS evaluation</td>
<td>No excessive HR rise; no orthostatic hypotension</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Quantitative sensory testing (QST)</td>
<td>Thermal threshold testing; research and specialized centers</td>
<td>Normal thermal detection thresholds</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Thermoregulatory sweat test (TST)</td>
<td>Global sudomotor evaluation if QSART equivocal</td>
<td>Normal sweat distribution</td>
<td>Cardiac instability</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Corneal confocal microscopy</td>
<td>Non-invasive small fiber assessment; research tool</td>
<td>Normal corneal nerve fiber density and length</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="2c-rarespecialized">2C. Rare/Specialized<a class="headerlink" href="#2c-rarespecialized" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMG</td>
<td>If large fiber involvement suspected; atypical features</td>
<td>Normal (SFN spares motor and large sensory fibers)</td>
<td>Anticoagulation (relative)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>MRI spine (cervical/thoracic)</td>
<td>Ganglionopathy pattern; non-length-dependent SFN</td>
<td>Normal dorsal root ganglia; no dorsal column signal</td>
<td>MRI contraindications</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>MRI neurography</td>
<td>Research; visualize small nerves</td>
<td>No nerve enlargement or signal abnormality</td>
<td>MRI contraindications</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>PET-CT</td>
<td>Sarcoidosis or malignancy suspected; paraneoplastic evaluation</td>
<td>No abnormal uptake</td>
<td>Pregnancy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Echocardiogram</td>
<td>Amyloidosis suspected (cardiomyopathy screening)</td>
<td>No infiltrative cardiomyopathy features</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Cardiac MRI</td>
<td>Cardiac amyloidosis evaluation if echo abnormal</td>
<td>No amyloid infiltration</td>
<td>MRI contraindications; devices</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="3-treatment">3. TREATMENT<a class="headerlink" href="#3-treatment" title="Permanent link">&para;</a></h2>
<h3 id="3a-acuteemergent">3A. Acute/Emergent<a class="headerlink" href="#3a-acuteemergent" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV fluids</td>
<td>IV</td>
<td>Acute orthostatic hypotension with symptoms</td>
<td>Normal saline bolus :: IV :: :: 500-1000 mL NS bolus for symptomatic orthostatic hypotension; avoid in heart failure</td>
<td>Heart failure; volume overload</td>
<td>Volume status; BP response</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Pain crisis management</td>
<td>IV/PO</td>
<td>Severe acute neuropathic pain flare not responding to outpatient regimen</td>
<td>Multimodal :: IV/PO :: :: IV lidocaine infusion (1-3 mg/kg/hr) if refractory; avoid chronic opioids</td>
<td>Lidocaine: cardiac conduction abnormality</td>
<td>Pain scores; cardiac monitoring for lidocaine</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Glucose management</td>
<td>Various</td>
<td>Acute presentation with new diabetes diagnosis</td>
<td>Per protocol :: Various :: :: Initiate diabetes management; hypoglycemia causes SFN flare</td>
<td>Per specific agent</td>
<td>Glucose</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-neuropathic-pain-first-line">3B. Symptomatic Treatments (Neuropathic Pain - First-line)<a class="headerlink" href="#3b-symptomatic-treatments-neuropathic-pain-first-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duloxetine</td>
<td>PO</td>
<td>First-line for neuropathic pain; also treats depression/anxiety common in SFN</td>
<td>30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day</td>
<td>MAOIs; uncontrolled narrow-angle glaucoma; severe renal impairment (CrCl &lt;30)</td>
<td>Hepatic function; BP; suicidal ideation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>PO</td>
<td>First-line for neuropathic pain; FDA-approved for postherpetic neuralgia and DPN</td>
<td>50 mg TID; 75 mg BID; 100 mg TID; 150 mg BID; 200 mg TID :: PO :: :: Start 50 mg TID or 75 mg BID; titrate q3-7d; max 300 mg/day; reduce if CrCl &lt;60</td>
<td>Angioedema to pregabalin/gabapentin</td>
<td>Dizziness, somnolence, weight gain, peripheral edema</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>PO</td>
<td>First-line; less expensive alternative to pregabalin</td>
<td>300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID; 1200 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1800-3600 mg/day divided TID; reduce if CrCl &lt;60</td>
<td>Severe renal impairment (dose adjust required)</td>
<td>Sedation, dizziness, ataxia, edema</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>PO</td>
<td>TCA for neuropathic pain; helps insomnia; inexpensive</td>
<td>10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS; max 150 mg</td>
<td>Cardiac conduction disease; recent MI; urinary retention; narrow-angle glaucoma; elderly (high anticholinergic burden)</td>
<td>ECG if age &gt;40 or cardiac history; anticholinergic side effects</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>PO</td>
<td>TCA with less sedation and anticholinergic effects than amitriptyline</td>
<td>10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS</td>
<td>Cardiac conduction disease; recent MI; urinary retention; narrow-angle glaucoma</td>
<td>ECG if dose &gt;100 mg/day or cardiac risk factors</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Venlafaxine XR</td>
<td>PO</td>
<td>SNRI alternative to duloxetine</td>
<td>37.5 mg daily; 75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 150-225 mg daily</td>
<td>MAOIs; uncontrolled hypertension</td>
<td>BP at higher doses; discontinuation syndrome if stopped abruptly</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3c-second-linerefractory-neuropathic-pain">3C. Second-line/Refractory (Neuropathic Pain)<a class="headerlink" href="#3c-second-linerefractory-neuropathic-pain" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsaicin 8% patch (Qutenza)</td>
<td>Topical</td>
<td>Localized neuropathic pain; add-on therapy</td>
<td>Apply for 30-60 min :: Topical :: :: Applied by trained healthcare provider; pre-treat with topical anesthetic; may repeat q3mo</td>
<td>Application to face/mucous membranes; broken skin</td>
<td>Pain/burning during application; transient BP increase</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Lidocaine 5% patch</td>
<td>Topical</td>
<td>Localized pain; adjunctive therapy; allodynia</td>
<td>1-3 patches daily :: Topical :: :: Apply to most painful area; up to 3 patches for 12h on/12h off</td>
<td>Allergy to local anesthetics; damaged skin</td>
<td>Skin irritation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>PO</td>
<td>Sodium channel blocker; some evidence in SFN</td>
<td>25 mg daily; 50 mg daily; 100 mg BID; 200 mg BID :: PO :: :: Start 25 mg daily x 2wk; then 50 mg daily x 2wk; increase by 50 mg q2wk; max 400 mg/day</td>
<td>SJS/TEN history; valproate use (reduce dose by 50%)</td>
<td>RASH (especially first 8 weeks) - stop immediately if rash</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Lacosamide</td>
<td>PO</td>
<td>Sodium channel blocker; well-tolerated</td>
<td>50 mg BID; 100 mg BID; 150 mg BID; 200 mg BID :: PO :: :: Start 50 mg BID; increase by 50 mg/day weekly; max 400 mg/day</td>
<td>Second or third degree AV block (without pacemaker)</td>
<td>ECG for PR prolongation; dizziness</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>PO</td>
<td>Sodium channel blocker; limited evidence for SFN specifically</td>
<td>100 mg BID; 200 mg BID; 400 mg BID :: PO :: :: Start 100 mg BID; titrate by 200 mg/wk; max 1200 mg/day</td>
<td>AV block; bone marrow suppression; HLA-B*1502 in Asian patients (SJS risk)</td>
<td>CBC, LFTs, sodium; drug interactions (CYP3A4 inducer)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Mexiletine</td>
<td>PO</td>
<td>Sodium channel blocker; especially if SCN9A mutation suspected</td>
<td>150 mg TID; 200 mg TID; 300 mg TID :: PO :: :: Start 150 mg TID; titrate by 150 mg q3d; max 1200 mg/day; take with food</td>
<td>Cardiomyopathy; second/third degree AV block</td>
<td>ECG; arrhythmia monitoring</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Desipramine</td>
<td>PO</td>
<td>TCA with minimal anticholinergic effects</td>
<td>25 mg qHS; 50 mg qHS; 75 mg qHS; 100 mg qHS :: PO :: :: Start 25 mg qHS; titrate by 25 mg q1-2wk; target 50-100 mg</td>
<td>Same as other TCAs</td>
<td>ECG; drug levels available if needed</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Tramadol</td>
<td>PO</td>
<td>Moderate pain; opioid-like with serotonergic properties</td>
<td>50 mg q6h PRN; 100 mg ER BID :: PO :: :: Start 50 mg q6h PRN; max 400 mg/day; reduce if renal/hepatic impairment</td>
<td>Seizure disorder; concurrent MAOIs/SSRIs (serotonin syndrome risk)</td>
<td>Seizures, serotonin syndrome, constipation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Tapentadol ER</td>
<td>PO</td>
<td>Refractory pain; mu-opioid agonist with norepinephrine reuptake inhibition</td>
<td>50 mg BID; 100 mg BID; 150 mg BID; 200 mg BID :: PO :: :: Start 50 mg BID; titrate by 50 mg BID q3d; max 500 mg/day</td>
<td>Severe respiratory depression; MAOIs; paralytic ileus</td>
<td>Respiratory status, constipation, sedation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Combination therapy</td>
<td>Various</td>
<td>Inadequate response to monotherapy</td>
<td>Combine agents from different classes :: Various :: :: Gabapentinoid + SNRI; TCA + gabapentinoid; use lower doses of each</td>
<td>Per individual agents</td>
<td>Additive side effects; falls in elderly</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Low-dose naltrexone (LDN)</td>
<td>PO</td>
<td>Emerging evidence for neuropathic pain; anti-inflammatory</td>
<td>1.5 mg qHS; 3 mg qHS; 4.5 mg qHS :: PO :: :: Start 1.5 mg qHS; increase by 1.5 mg q2wk; max 4.5 mg; compounded</td>
<td>Current opioid use; hepatic impairment</td>
<td>Vivid dreams, insomnia (take in AM if occurs)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Spinal cord stimulation</td>
<td>Implant</td>
<td>Refractory SFN pain; failed multiple medications</td>
<td>Per implant protocol :: Implant :: :: Trial stimulation before permanent implant; high-frequency or burst stimulation preferred</td>
<td>Infection; coagulopathy; psychiatric instability</td>
<td>Device function; pain relief</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3d-autonomic-symptom-management">3D. Autonomic Symptom Management<a class="headerlink" href="#3d-autonomic-symptom-management" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Pre-Treatment Requirements</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fludrocortisone</td>
<td>PO</td>
<td>Orthostatic hypotension; volume expansion</td>
<td>0.1 mg daily; 0.2 mg daily :: PO :: :: Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg</td>
<td>Check potassium; assess volume status</td>
<td>Heart failure; hypertension; hypokalemia</td>
<td>Weight, BP supine and standing, potassium, edema</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Midodrine</td>
<td>PO</td>
<td>Orthostatic hypotension; alpha-1 agonist vasoconstrictor</td>
<td>2.5 mg TID; 5 mg TID; 10 mg TID :: PO :: :: Start 2.5 mg TID (with meals); titrate to 5-10 mg TID; last dose 4h before bed</td>
<td>None specific</td>
<td>Severe cardiac disease; urinary retention; supine hypertension</td>
<td>Supine BP (check for supine hypertension); avoid at bedtime</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Droxidopa (Northera)</td>
<td>PO</td>
<td>Neurogenic orthostatic hypotension; FDA-approved for autonomic failure</td>
<td>100 mg TID; 200 mg TID; 300 mg TID; 400 mg TID; 600 mg TID :: PO :: :: Start 100 mg TID; titrate by 100 mg/day q24-48h; max 600 mg TID</td>
<td>None specific</td>
<td>Supine hypertension (severe)</td>
<td>Supine BP; avoid lying flat for 2h after dose</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Pyridostigmine</td>
<td>PO</td>
<td>Orthostatic hypotension; enhances ganglionic transmission</td>
<td>30 mg TID; 60 mg TID :: PO :: :: Start 30 mg TID; may increase to 60 mg TID; modest BP effect but no supine hypertension</td>
<td>None specific</td>
<td>Mechanical GI/GU obstruction; bradyarrhythmia</td>
<td>Cholinergic effects (diarrhea, salivation)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Compression stockings</td>
<td>External</td>
<td>Orthostatic hypotension; venous pooling</td>
<td>Waist-high 30-40 mmHg :: External :: :: Waist-high preferred over knee-high; put on before rising; 30-40 mmHg compression</td>
<td>Peripheral arterial disease (ABI &lt;0.5)</td>
<td>Skin breakdown; PAD</td>
<td>Skin integrity; ABI if arterial disease suspected</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Oxybutynin</td>
<td>PO</td>
<td>Bladder urgency/frequency</td>
<td>5 mg BID; 5 mg TID; 10 mg XL daily :: PO :: :: Start 5 mg BID or 10 mg XL daily; max 30 mg/day</td>
<td>Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction</td>
<td>Cognitive effects in elderly; dry mouth</td>
<td>Anticholinergic effects; cognition in elderly</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Solifenacin</td>
<td>PO</td>
<td>Bladder urgency; better tolerated anticholinergic</td>
<td>5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily</td>
<td>Same as oxybutynin; severe hepatic impairment</td>
<td>Same as oxybutynin but less cognitive</td>
<td>Anticholinergic effects</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Mirabegron</td>
<td>PO</td>
<td>Bladder urgency; beta-3 agonist (non-anticholinergic)</td>
<td>25 mg daily; 50 mg daily :: PO :: :: Start 25 mg daily; may increase to 50 mg daily</td>
<td>Uncontrolled hypertension; severe hepatic impairment</td>
<td>BP; urinary retention</td>
<td>-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>PO</td>
<td>Gastroparesis; prokinetic</td>
<td>5 mg AC; 10 mg AC :: PO :: :: 5-10 mg 30 min before meals and at bedtime; limit to &lt;12 weeks</td>
<td>Tardive dyskinesia (limit duration); GI obstruction; Parkinson disease</td>
<td>Tardive dyskinesia; extrapyramidal symptoms</td>
<td>-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Domperidone</td>
<td>PO</td>
<td>Gastroparesis; prokinetic with less CNS effects</td>
<td>10 mg TID :: PO :: :: 10 mg TID before meals; not FDA-approved (requires IND or international pharmacy)</td>
<td>QT prolongation; ventricular arrhythmia</td>
<td>ECG for QT; arrhythmia</td>
<td>-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Erythromycin</td>
<td>PO</td>
<td>Gastroparesis; motilin receptor agonist</td>
<td>250 mg TID :: PO :: :: 250 mg PO TID before meals; short-term use due to tachyphylaxis</td>
<td>QT prolongation; drug interactions</td>
<td>ECG; GI upset; tachyphylaxis limits long-term use</td>
<td>-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Sildenafil</td>
<td>PO</td>
<td>Erectile dysfunction in autonomic SFN</td>
<td>25 mg PRN; 50 mg PRN; 100 mg PRN :: PO :: :: Start 25-50 mg 1h before activity; max 100 mg; avoid with nitrates</td>
<td>Nitrate use; severe cardiovascular disease</td>
<td>Cardiovascular status; vision changes</td>
<td>-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;"></td>
</tr>
</tbody>
</table>
<h3 id="3e-disease-modifying-etiology-targeted-therapies">3E. Disease-Modifying / Etiology-Targeted Therapies<a class="headerlink" href="#3e-disease-modifying-etiology-targeted-therapies" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Pre-Treatment Requirements</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycemic control optimization</td>
<td>Various</td>
<td>Diabetes/prediabetes-associated SFN</td>
<td>Per diabetes guidelines :: Various :: :: Lifestyle first for prediabetes; HbA1c &lt;7% target; tighter control slows progression</td>
<td>Diabetes education</td>
<td>Hypoglycemia risk</td>
<td>HbA1c q3-6mo; glucose monitoring</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>IVIG</td>
<td>IV</td>
<td>Autoimmune SFN (Sjogren-associated; anti-FGFR3+; idiopathic with evidence of inflammation)</td>
<td>2 g/kg divided over 2-5 days :: IV :: :: 2 g/kg divided over 2-5 days monthly; limited evidence; consider trial</td>
<td>Check IgA level (IgA-deficient patients need IgA-depleted product)</td>
<td>IgA deficiency (use IgA-depleted); renal impairment; hypercoagulable state</td>
<td>Renal function; thrombotic risk; headache</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Enzyme replacement therapy (Fabry disease)</td>
<td>IV</td>
<td>Fabry disease-associated SFN</td>
<td>Agalsidase beta (Fabrazyme) 1 mg/kg IV q2wk :: IV :: :: Lifelong therapy; infusion reactions common early</td>
<td>None</td>
<td>None absolute</td>
<td>Infusion reactions; anti-drug antibodies</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Tafamidis (Vyndamax/Vyndaqel)</td>
<td>PO</td>
<td>Hereditary and wild-type TTR amyloidosis with polyneuropathy</td>
<td>80 mg daily; 61 mg daily :: PO :: :: 80 mg (Vyndamax) or 61 mg (Vyndaqel) PO daily; TTR stabilizer</td>
<td>Genetic confirmation of TTR amyloidosis</td>
<td>None</td>
<td>Cardiac function; neuropathy progression</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Inotersen/Patisiran</td>
<td>SC/IV</td>
<td>Hereditary TTR amyloidosis with polyneuropathy</td>
<td>Per prescribing protocol :: SC/IV :: :: Inotersen 284 mg SC weekly; Patisiran 0.3 mg/kg IV q3wk</td>
<td>TTR gene mutation confirmed; specialist management</td>
<td>Thrombocytopenia (inotersen); infusion reactions</td>
<td>Platelets (inotersen); hepatic function</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Gluten-free diet</td>
<td>Diet</td>
<td>Celiac disease-associated SFN</td>
<td>Strict gluten-free :: Diet :: :: Lifelong strict gluten-free diet; dietitian referral; neuropathy may stabilize/improve</td>
<td>Celiac confirmation</td>
<td>None</td>
<td>TTG-IgA levels; symptom response</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>B12 supplementation</td>
<td>PO/IM</td>
<td>B12 deficiency-associated SFN</td>
<td>1000 mcg daily PO; 1000 mcg IM monthly :: PO/IM :: :: 1000-2000 mcg PO daily; or 1000 mcg IM weekly x 4, then monthly if poor absorption</td>
<td>None</td>
<td>None</td>
<td>B12 and MMA levels q3-6mo until stable</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Immunosuppression (Sjogren's)</td>
<td>Various</td>
<td>Sjogren's-associated SFN with systemic disease activity</td>
<td>Per rheumatology :: Various :: :: Hydroxychloroquine, methotrexate, rituximab; coordinate with rheumatology</td>
<td>Rheumatology co-management</td>
<td>Per specific agent</td>
<td>Per specific agent</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Alpha-lipoic acid</td>
<td>PO</td>
<td>Antioxidant; some evidence in painful neuropathy; European guidelines</td>
<td>600 mg daily :: PO :: :: 600 mg PO daily; may take 3-6 months for effect; limited evidence</td>
<td>None</td>
<td>GI upset</td>
<td>May enhance hypoglycemia in diabetics</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="4-other-recommendations">4. OTHER RECOMMENDATIONS<a class="headerlink" href="#4-other-recommendations" title="Permanent link">&para;</a></h2>
<h3 id="4a-referrals-consults">4A. Referrals &amp; Consults<a class="headerlink" href="#4a-referrals-consults" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuromuscular specialist for skin biopsy interpretation and complex SFN management</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Rheumatology if Sjogren's, lupus, or other connective tissue disease suspected</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Endocrinology if diabetes/prediabetes for glycemic optimization and metabolic management</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Genetics counselor if hereditary etiology suspected (Fabry, TTR amyloidosis, SCN9A channelopathies)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Gastroenterology for celiac confirmation, gastroparesis management, or liver biopsy if amyloid suspected</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Cardiology if TTR amyloidosis suspected or autonomic symptoms with cardiac involvement</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Pain management for refractory neuropathic pain and interventional options (spinal cord stimulation)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Physical therapy for balance training, strengthening, and fall prevention</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Autonomic disorders specialist if complex autonomic symptoms (POTS, orthostatic hypotension)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Psychiatry/psychology for chronic pain coping and comorbid depression/anxiety management</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Hematology/oncology if amyloidosis confirmed for staging and treatment</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="4b-patient-instructions">4B. Patient Instructions<a class="headerlink" href="#4b-patient-instructions" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report any new weakness, gait difficulty, or falls as these may indicate progression to large fiber involvement</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Monitor for signs of infection in feet (redness, warmth, drainage) if sensation is impaired</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Keep a pain diary to track triggers, severity, and medication response</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Rise slowly from sitting or lying to prevent falls from orthostatic hypotension</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Increase salt and fluid intake (2-3L/day, 6-10g sodium) if orthostatic hypotension present (unless contraindicated)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Wear compression stockings before rising in the morning if orthostatic hypotension diagnosed</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Take all prescribed pain medications as directed; do not stop gabapentinoids or SNRIs abruptly</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Avoid excessive heat exposure which can worsen symptoms; stay hydrated in warm weather</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Return if severe headache, vision changes, or syncope develop (may indicate medication side effects or disease progression)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<h3 id="4c-lifestyle-prevention">4C. Lifestyle &amp; Prevention<a class="headerlink" href="#4c-lifestyle-prevention" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strict glycemic control (HbA1c &lt;7% or &lt;5.7% if prediabetes) to prevent progression; lifestyle modifications first</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Alcohol cessation as alcohol independently causes and worsens small fiber neuropathy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Smoking cessation as smoking impairs nerve regeneration and worsens outcomes</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Regular low-impact exercise (swimming, stationary bike, walking) to improve pain and maintain function</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Healthy diet (Mediterranean or DASH) to optimize metabolic health and reduce inflammation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Weight management as metabolic syndrome is associated with SFN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Sleep hygiene to improve sleep quality; chronic pain worsens with poor sleep</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Stress reduction techniques (mindfulness, meditation) as stress can amplify pain perception</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Fall prevention with home safety evaluation given proprioceptive deficits and orthostatic hypotension</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Avoid B6 (pyridoxine) supplementation above RDA (1.3-2 mg/day) as excess causes neuropathy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="section-b-reference">SECTION B: REFERENCE<a class="headerlink" href="#section-b-reference" title="Permanent link">&para;</a></h2>
<hr />
<h2 id="5-differential-diagnosis">5. DIFFERENTIAL DIAGNOSIS<a class="headerlink" href="#5-differential-diagnosis" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Alternative Diagnosis</th>
<th>Key Distinguishing Features</th>
<th>Tests to Differentiate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic polyneuropathy (large fiber)</td>
<td>NCS abnormal; mixed sensorimotor findings; more numbness than pain</td>
<td>EMG/NCS shows axonal polyneuropathy</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>Widespread pain; tender points; normal skin biopsy; chronic fatigue</td>
<td>ACR criteria; normal IENFD on skin biopsy</td>
</tr>
<tr>
<td>Complex regional pain syndrome (CRPS)</td>
<td>Regional rather than length-dependent; swelling, color changes, dystrophy</td>
<td>Budapest criteria; regional distribution</td>
</tr>
<tr>
<td>Erythromelalgia</td>
<td>Intermittent burning with redness and warmth; triggered by heat; may have SCN9A mutation</td>
<td>Clinical pattern; genetic testing if suspected</td>
</tr>
<tr>
<td>Central sensitization syndromes</td>
<td>Normal peripheral testing; pain out of proportion to objective findings</td>
<td>QST pattern; skin biopsy normal</td>
</tr>
<tr>
<td>Psychogenic/functional sensory symptoms</td>
<td>Non-anatomical distribution; inconsistent findings; psychiatric comorbidity</td>
<td>Careful neurological exam; normal objective testing</td>
</tr>
<tr>
<td>Vitamin B12 deficiency</td>
<td>May have subacute combined degeneration; cognitive changes; macrocytic anemia</td>
<td>B12, MMA levels; MRI spine</td>
</tr>
<tr>
<td>Lyme disease</td>
<td>Endemic area; prior tick bite; rash history; may have radiculopathy</td>
<td>Lyme serology (ELISA + Western blot)</td>
</tr>
<tr>
<td>Hereditary sensory neuropathy (HSAN)</td>
<td>Family history; anhidrosis; painless injuries; mutilating features</td>
<td>Genetic testing (HSAN genes)</td>
</tr>
<tr>
<td>Burning mouth syndrome</td>
<td>Isolated to oral mucosa; taste changes; dry mouth</td>
<td>Location-specific; oral exam</td>
</tr>
<tr>
<td>Restless legs syndrome</td>
<td>Urge to move legs; worse at rest/night; relief with movement</td>
<td>Clinical criteria; may coexist with SFN</td>
</tr>
<tr>
<td>Vasculitic neuropathy</td>
<td>Asymmetric; mononeuritis multiplex pattern; systemic symptoms; rapid onset</td>
<td>Nerve biopsy; inflammatory markers; angiography</td>
</tr>
<tr>
<td>Paraneoplastic sensory ganglionopathy</td>
<td>Subacute onset; asymmetric; non-length-dependent; cancer history/risk</td>
<td>Anti-Hu antibodies; CT chest/abdomen/pelvis</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-monitoring-parameters">6. MONITORING PARAMETERS<a class="headerlink" href="#6-monitoring-parameters" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target/Threshold</th>
<th>Action if Abnormal</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain scores (NRS, VAS, BPI)</td>
<td>Each visit</td>
<td>50%+ reduction or functional improvement</td>
<td>Adjust medications; consider combination or referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>HbA1c (if diabetes/prediabetes)</td>
<td>Every 3-6 months</td>
<td>&lt;7% (or &lt;5.7% if prediabetes)</td>
<td>Intensify glycemic management</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Orthostatic vitals (lying, sitting, standing)</td>
<td>Each visit if autonomic symptoms</td>
<td>SBP drop &lt;20 mmHg; no symptoms</td>
<td>Adjust autonomic medications; hydration; compression</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Repeat skin biopsy (IENFD)</td>
<td>Every 1-2 years if monitoring disease course</td>
<td>Stable or improved IENFD</td>
<td>Intensify etiology treatment if declining</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Autonomic symptoms inventory</td>
<td>Each visit</td>
<td>Stable or improved</td>
<td>Adjust autonomic treatments; workup new symptoms</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>ECG</td>
<td>Baseline if on TCAs or sodium channel blockers; periodically</td>
<td>Normal PR, QRS, QTc intervals</td>
<td>Dose reduction or discontinuation if prolonged intervals</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Renal function (eGFR)</td>
<td>Every 6-12 months</td>
<td>eGFR &gt;60 or stable</td>
<td>Adjust medication doses; nephrology referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Potassium (if on fludrocortisone)</td>
<td>Monthly initially, then every 3-6 months</td>
<td>3.5-5.0 mEq/L</td>
<td>Supplement potassium; reduce fludrocortisone dose</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Weight and edema</td>
<td>Each visit</td>
<td>Stable weight; no edema</td>
<td>Adjust pregabalin/gabapentin or autonomic meds</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Depression screen (PHQ-9)</td>
<td>Every 6-12 months</td>
<td>&lt;5 (no depression)</td>
<td>Mental health referral; consider duloxetine/venlafaxine</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Falls assessment</td>
<td>Each visit</td>
<td>No falls</td>
<td>PT referral; home safety; reduce sedating medications</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="7-disposition-criteria">7. DISPOSITION CRITERIA<a class="headerlink" href="#7-disposition-criteria" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Disposition</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge home</td>
<td>Symptoms stable; pain controlled; autonomic symptoms not causing hemodynamic instability; follow-up arranged</td>
</tr>
<tr>
<td>Admit to floor</td>
<td>Severe uncontrolled pain requiring IV medications; syncope from orthostatic hypotension; new diagnosis requiring urgent workup (suspected amyloidosis with cardiac involvement)</td>
</tr>
<tr>
<td>Admit to ICU</td>
<td>Hemodynamically unstable from autonomic dysfunction; severe symptomatic bradycardia or hypotension</td>
</tr>
<tr>
<td>Outpatient follow-up</td>
<td>Every 3-6 months for medication optimization; annually for etiology reassessment if initially idiopathic</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="8-evidence-references">8. EVIDENCE &amp; REFERENCES<a class="headerlink" href="#8-evidence-references" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Evidence Level</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin biopsy (IENFD) as diagnostic standard for SFN</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/20298428/">Lauria et al. European Journal of Neurology 2010</a></td>
</tr>
<tr>
<td>QSART for sudomotor function assessment in SFN</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/6308464/">Low et al. Muscle &amp; Nerve 1983</a></td>
</tr>
<tr>
<td>Impaired glucose tolerance as cause of SFN</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/11723275/">Singleton et al. Neurology 2001</a></td>
</tr>
<tr>
<td>Sjogren syndrome associated with SFN</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/15984030/">Chai et al. Annals of Neurology 2005</a></td>
</tr>
<tr>
<td>Duloxetine for neuropathic pain</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/24399144/">Lunn et al. Cochrane 2014</a></td>
</tr>
<tr>
<td>Gabapentin for neuropathic pain</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28597471/">Wiffen et al. Cochrane 2017</a></td>
</tr>
<tr>
<td>Pregabalin for neuropathic pain</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30673120/">Derry et al. Cochrane 2019</a></td>
</tr>
<tr>
<td>TCAs for neuropathic pain</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/25879104/">Moore et al. Cochrane 2015</a></td>
</tr>
<tr>
<td>Fludrocortisone for orthostatic hypotension</td>
<td>Class II, Level C</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/29666232/">Freeman et al. Neurology 2018 Consensus Statement</a></td>
</tr>
<tr>
<td>Midodrine for orthostatic hypotension</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/9463419/">Wright et al. Am Heart J 1998</a></td>
</tr>
<tr>
<td>Droxidopa for neurogenic orthostatic hypotension</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/25646278/">Biaggioni et al. Neurology 2015</a></td>
</tr>
<tr>
<td>IVIG for autoimmune SFN</td>
<td>Class III, Level C</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/24750390/">Liu et al. J Periph Nerv Syst 2014</a></td>
</tr>
<tr>
<td>Fabry disease as cause of SFN</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/22452838/">Biegstraaten et al. Orphanet J Rare Dis 2012</a></td>
</tr>
<tr>
<td>TTR amyloidosis neuropathy treatment</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/29972757/">Adams et al. NEJM 2018 (Patisiran trial)</a></td>
</tr>
<tr>
<td>Sodium channelopathies (SCN9A) in SFN</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/22522478/">Faber et al. Ann Neurol 2012</a></td>
</tr>
</tbody>
</table>
<hr />
<h2 id="change-log">CHANGE LOG<a class="headerlink" href="#change-log" title="Permanent link">&para;</a></h2>
<p><strong>v1.0 (January 27, 2026)</strong>
- Initial template creation
- Comprehensive etiologic workup (diabetes, Sjogren's, amyloidosis, Fabry, celiac)
- Diagnostic approach with skin biopsy and autonomic testing
- Neuropathic pain treatment with structured dosing format
- Autonomic symptom management section
- Disease-modifying therapies for treatable causes
- Differentiation of length-dependent vs non-length-dependent patterns</p>
<hr />
<h2 id="appendix-a-sfn-diagnostic-criteria">APPENDIX A: SFN Diagnostic Criteria<a class="headerlink" href="#appendix-a-sfn-diagnostic-criteria" title="Permanent link">&para;</a></h2>
<h3 id="clinical-features-suggesting-sfn">Clinical Features Suggesting SFN<a class="headerlink" href="#clinical-features-suggesting-sfn" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Symptom Category</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Positive sensory symptoms</strong></td>
<td>Burning pain; electric shock sensations; tingling; allodynia; hyperalgesia</td>
</tr>
<tr>
<td><strong>Negative sensory symptoms</strong></td>
<td>Numbness; thermal hypoesthesia (can't feel hot/cold)</td>
</tr>
<tr>
<td><strong>Autonomic symptoms</strong></td>
<td>Dry eyes/mouth; sweating abnormalities; orthostatic intolerance; GI dysmotility; urinary dysfunction; erectile dysfunction</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Length-dependent (feet &gt; hands) OR non-length-dependent (patchy, proximal, asymmetric)</td>
</tr>
</tbody>
</table>
<h3 id="diagnostic-certainty-levels">Diagnostic Certainty Levels<a class="headerlink" href="#diagnostic-certainty-levels" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Level</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Possible SFN</strong></td>
<td>Clinical symptoms and signs compatible with SFN</td>
</tr>
<tr>
<td><strong>Probable SFN</strong></td>
<td>Clinical features + abnormal QST thermal thresholds OR abnormal QSART</td>
</tr>
<tr>
<td><strong>Definite SFN</strong></td>
<td>Clinical features + reduced IENFD on skin biopsy below age/sex/site normative values</td>
</tr>
</tbody>
</table>
<h3 id="length-dependent-vs-non-length-dependent-ganglionopathy-pattern">Length-Dependent vs Non-Length-Dependent (Ganglionopathy) Pattern<a class="headerlink" href="#length-dependent-vs-non-length-dependent-ganglionopathy-pattern" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Feature</th>
<th>Length-Dependent</th>
<th>Non-Length-Dependent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution</td>
<td>Distal &gt; proximal; symmetric; feet before hands</td>
<td>Patchy; asymmetric; proximal involvement; face/trunk</td>
</tr>
<tr>
<td>Common causes</td>
<td>Diabetes; metabolic; toxic; idiopathic</td>
<td>Sjogren's; paraneoplastic; autoimmune; amyloidosis</td>
</tr>
<tr>
<td>Prognosis</td>
<td>Often slowly progressive</td>
<td>May be more aggressive; depends on etiology</td>
</tr>
<tr>
<td>Workup focus</td>
<td>Metabolic causes</td>
<td>Autoimmune and systemic causes</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-b-skin-biopsy-interpretation">APPENDIX B: Skin Biopsy Interpretation<a class="headerlink" href="#appendix-b-skin-biopsy-interpretation" title="Permanent link">&para;</a></h2>
<h3 id="procedure">Procedure<a class="headerlink" href="#procedure" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Sites:</strong> Distal leg (10 cm above lateral malleolus) and proximal thigh (20 cm below iliac spine)</li>
<li><strong>Technique:</strong> 3mm punch biopsy; send to laboratory with PGP9.5 immunostaining capability</li>
<li><strong>Processing:</strong> Fix in PLP or Zamboni's fixative; immunostain for PGP9.5</li>
</ul>
<h3 id="interpretation">Interpretation<a class="headerlink" href="#interpretation" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Result</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IENFD below 5th percentile for age/sex/site</td>
<td>Diagnostic of SFN</td>
</tr>
<tr>
<td>IENFD at lower range of normal (5th-10th percentile)</td>
<td>Borderline; correlate clinically</td>
</tr>
<tr>
<td>Distal/proximal IENFD ratio &gt;2:1</td>
<td>Length-dependent pattern</td>
</tr>
<tr>
<td>Both sites equally reduced</td>
<td>Consider ganglionopathy or diffuse process</td>
</tr>
<tr>
<td>Sweat gland nerve fiber density reduced</td>
<td>Supports autonomic involvement</td>
</tr>
</tbody>
</table>
<h3 id="normative-values-approximate-use-laboratory-specific-norms">Normative Values (Approximate - Use Laboratory-Specific Norms)<a class="headerlink" href="#normative-values-approximate-use-laboratory-specific-norms" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Site</th>
<th>Typical 5th Percentile Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distal leg (age 20-40)</td>
<td>~8-9 fibers/mm</td>
</tr>
<tr>
<td>Distal leg (age 60-80)</td>
<td>~4-5 fibers/mm</td>
</tr>
<tr>
<td>Proximal thigh</td>
<td>Generally higher than distal leg</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-c-autonomic-testing-interpretation">APPENDIX C: Autonomic Testing Interpretation<a class="headerlink" href="#appendix-c-autonomic-testing-interpretation" title="Permanent link">&para;</a></h2>
<h3 id="qsart-quantitative-sudomotor-axon-reflex-test">QSART (Quantitative Sudomotor Axon Reflex Test)<a class="headerlink" href="#qsart-quantitative-sudomotor-axon-reflex-test" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Pattern</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced sweat volume at distal sites (foot) with normal proximal</td>
<td>Length-dependent autonomic SFN</td>
</tr>
<tr>
<td>Globally reduced sweat volumes</td>
<td>Diffuse autonomic involvement</td>
</tr>
<tr>
<td>Normal QSART</td>
<td>Does not exclude SFN (may have sensory-predominant)</td>
</tr>
</tbody>
</table>
<h3 id="autonomic-reflex-screen-components">Autonomic Reflex Screen Components<a class="headerlink" href="#autonomic-reflex-screen-components" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>What It Measures</th>
<th>Abnormality in SFN</th>
</tr>
</thead>
<tbody>
<tr>
<td>QSART</td>
<td>Postganglionic sudomotor function</td>
<td>Reduced sweat volumes</td>
</tr>
<tr>
<td>Heart rate variability</td>
<td>Cardiovagal function</td>
<td>Reduced HRV to deep breathing</td>
</tr>
<tr>
<td>Valsalva maneuver</td>
<td>Cardiovagal and adrenergic function</td>
<td>Abnormal BP/HR response</td>
</tr>
<tr>
<td>Tilt table test</td>
<td>Adrenergic function; orthostatic tolerance</td>
<td>Orthostatic hypotension or POTS</td>
</tr>
</tbody>
</table>
<h3 id="pots-postural-orthostatic-tachycardia-syndrome-criteria">POTS (Postural Orthostatic Tachycardia Syndrome) Criteria<a class="headerlink" href="#pots-postural-orthostatic-tachycardia-syndrome-criteria" title="Permanent link">&para;</a></h3>
<ul>
<li>HR increase ≥30 bpm (or ≥40 bpm if age 12-19) within 10 minutes of standing</li>
<li>Absence of orthostatic hypotension (SBP drop &lt;20 mmHg)</li>
<li>Symptoms of orthostatic intolerance</li>
<li>Duration ≥6 months</li>
</ul>







  
  






                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/blondarb/neuro-plans" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      
      <script id="__config" type="application/json">{"annotate": null, "base": "../..", "features": ["navigation.instant", "navigation.tracking", "navigation.sections", "navigation.expand", "navigation.top", "search.suggest", "search.highlight", "content.code.copy"], "search": "../../assets/javascripts/workers/search.2c215733.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.79ae519e.min.js"></script>
      
        <script src="../../assets/js/comments.js"></script>
      
    
  </body>
</html>